Tyra Biosciences Announces Promising Preclinical Results for TYRA-300 in FGFR3-related Skeletal Dysplasia at ENDO 2025

Reuters

07/09

<a href="https://laohu8.com/S/TYRA">Tyra Biosciences</a> Announces Promising Preclinical Results for TYRA-300 in FGFR3-related Skeletal Dysplasia at ENDO 2025

Tyra Biosciences Inc., a clinical-stage biotechnology company, has announced the upcoming presentation of preclinical results for their investigational drug, TYRA-300, at The Endocrine Society's Annual Meeting (ENDO 2025) in San Francisco, CA. The late-breaking poster presentation, titled "TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia," will be delivered by Dr. Jacqueline H. Starrett on July 13, 2025. This study focuses on the potential of TYRA-300 to address bone growth challenges associated with FGFR3-related skeletal dysplasia. The session will be part of the BONE AND MINERAL METABOLISM track, focusing on rare bone and genetic disorders. Further details and access to the poster will be available on Tyra Biosciences' website following the conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tyra Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA25235) on July 08, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2550578195"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550578195\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550578195?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-09 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550578195","market":"us","top_or_hot":-1,"title":"Tyra Biosciences Announces Promising Preclinical Results for TYRA-300 in FGFR3-related Skeletal Dysplasia at ENDO 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TYRA\">Tyra Biosciences</a> Announces Promising Preclinical Results for TYRA-300 in FGFR3-related Skeletal Dysplasia at ENDO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tyra Biosciences Inc., a clinical-stage biotechnology company, has announced the upcoming presentation of preclinical results for their investigational drug, TYRA-300, at The Endocrine Society's Annual Meeting (ENDO 2025) in San Francisco, CA. The late-breaking poster presentation, titled \"TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia,\" will be delivered by Dr. Jacqueline H. Starrett on July 13, 2025. This study focuses on the potential of TYRA-300 to address bone growth challenges associated with FGFR3-related skeletal dysplasia. The session will be part of the BONE AND MINERAL METABOLISM track, focusing on rare bone and genetic disorders. Further details and access to the poster will be available on Tyra Biosciences' website following the conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tyra Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA25235) on July 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tyra Biosciences Announces Promising Preclinical Results for TYRA-300 in FGFR3-related Skeletal Dysplasia at ENDO 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTyra Biosciences Announces Promising Preclinical Results for TYRA-300 in FGFR3-related Skeletal Dysplasia at ENDO 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-09 04:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TYRA\">Tyra Biosciences</a> Announces Promising Preclinical Results for TYRA-300 in FGFR3-related Skeletal Dysplasia at ENDO 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tyra Biosciences Inc., a clinical-stage biotechnology company, has announced the upcoming presentation of preclinical results for their investigational drug, TYRA-300, at The Endocrine Society's Annual Meeting (ENDO 2025) in San Francisco, CA. The late-breaking poster presentation, titled \"TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia,\" will be delivered by Dr. Jacqueline H. Starrett on July 13, 2025. This study focuses on the potential of TYRA-300 to address bone growth challenges associated with FGFR3-related skeletal dysplasia. The session will be part of the BONE AND MINERAL METABOLISM track, focusing on rare bone and genetic disorders. Further details and access to the poster will be available on Tyra Biosciences' website following the conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tyra Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA25235) on July 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TYRA","symbol_name":"Tyra Biosciences, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250708:nNDL5GD83w:1","article_id":"2550578195","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550578195","pubTimestamp":1752005140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tyra Biosciences Inc., a clinical-stage biotechnology company, has announced the upcoming presentation of preclinical results for their investigational drug, TYRA-300, at The Endocrine Society's Annual Meeting  in San Francisco, CA. The late-breaking poster presentation, titled \"TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia,\" will be delivered by Dr. Jacqueline H. Starrett on July 13, 2025. This study focuses on the potential of TYRA-300 to address bone growth challenges associated with FGFR3-related skeletal dysplasia. The session will be part of the BONE AND MINERAL METABOLISM track, focusing on rare bone and genetic disorders. Further details and access to the poster will be available on Tyra Biosciences' website following the conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TYRA":"Tyra Biosciences, Inc.","BK4139":"生物科技"},"translate_title":"Tyra Biosciences在ENDO 2025上宣布TYRA-300治疗FGFR3相关骨骼发育不良的临床前结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TYRA":0.9},"content_text":"Tyra Biosciences Announces Promising Preclinical Results for TYRA-300 in FGFR3-related Skeletal Dysplasia at ENDO 2025\n    \n\n        Tyra Biosciences Inc., a clinical-stage biotechnology company, has announced the upcoming presentation of preclinical results for their investigational drug, TYRA-300, at The Endocrine Society's Annual Meeting (ENDO 2025) in San Francisco, CA. The late-breaking poster presentation, titled \"TYRA-300 Promotes Bone Growth In Two Mouse Models Of FGFR3-related Skeletal Dysplasia,\" will be delivered by Dr. Jacqueline H. Starrett on July 13, 2025. This study focuses on the potential of TYRA-300 to address bone growth challenges associated with FGFR3-related skeletal dysplasia. The session will be part of the BONE AND MINERAL METABOLISM track, focusing on rare bone and genetic disorders. Further details and access to the poster will be available on Tyra Biosciences' website following the conference.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tyra Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA25235) on July 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}